# Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

> **NCT02864394** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 425 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02864394
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-07
- **Primary completion:** 2019-09-09
- **Final completion:** 2022-10-14
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864394, "Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02864394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*